Soticlestat as an adjunctive therapy in children and young adults with Dravet syndrome.

Key Points

• To evaluate the effectiveness and safety of soticlestat as an adjunctive therapy in patients with Dravet syndrome.
• Conducted a clinical trial comparing soticlestat to placebo
• Assessed seizure frequency and multiple secondary endpoints
• Monitored safety profile during the study
• Soticlestat showed a numerical benefit in reducing convulsive seizures compared to placebo
• Clinically meaningful benefits were identified across multiple secondary endpoints
• No new safety concerns were reported throughout the study.

Abstract